Table 1.
ASD Cohort characteristics by data source
| Characteristics | IBM marketScan® multi-state medicaid database (MDCD) | Optum® de-identified clinformatics® | ||
|---|---|---|---|---|
| N | % | N | % | |
| Total | 29,694 | 100 | 6719 | 100 |
| Age (years) mean. Std | 14.09 (12.17) | 15.04 (14.90) | ||
| 0–5 | 5806 | 19.55 | 1388 | 20.66 |
| 5–9 | 7706 | 25.95 | 1552 | 23.10 |
| 10–14 | 5763 | 19.41 | 1414 | 21.09 |
| 15–17 | 2411 | 8.12 | 752 | 11.19 |
| 18 and above | 8008 | 26.97 | 1610 | 23.96 |
| Race | ||||
| White | 17,169 | 57.82 | ||
| Black | 6847 | 23.06 | ||
| Unknown race | 5678 | 19.12% | ||
| Gender | ||||
| Male | 22,648 | 76.27 | 5125 | 76.28 |
| Female | 7046 | 23.73 | 1594 | 23.72 |
| Index year | ||||
| 2015 | 12,561 | 42.30 | 2,246 | 33.43 |
| 2016 | 17,133 | 57.70 | 2,469 | 36.75 |
| 2017 | 0 | – | 2,004 | 29.83 |
| Charlson index (mean, STD) | 0.36 (1.23) | 0.46 (1.38) | ||
| Treatments | ||||
| Any treatment | 25,978 | 87.5% | 5837 | 86.9% |
| Behavioral therapy | 22,165 | 74.64% | 4836 | 71.97% |
| Any Pharmacotherapy | 18,430 | 62.1% | 3951 | 58.8% |
| Centrally acting sympathomimetics | 7494 | 25.24% | 1746 | 25.99% |
| Imidazoline receptor agonists | 7016 | 23.63% | 1008 | 15.00% |
| Antipsychotics | 6134 | 20.66% | 1116 | 16.61% |
| Atypical antipsychotics | 5011 | 16.88% | 811 | 12.07% |
| Selective serotonin reuptake inhibitors | 4929 | 16.60% | 1698 | 25.27% |
| Anticonvulsant | 4285 | 14.43% | 1008 | 15.00% |
| Anxiolytics (excluding BZO) | 3227 | 10.87% | 9591 | 14.27% |
| Hypnotics and sedatives | 3073 | 10.35% | 498 | 7.41% |
| Other antidepressants | 2621 | 8.08% | 553 | 8.23% |
We report the proportion of base-line demographics and index year and treatment utilization in each data source